Sulfatinib for osteosarcoma that came back or won’t respond
Treatments studied
Part of Cancer clinical trials.
This early-phase study tests sulfatinib in children, teens, and young adults with high-grade osteosarcoma that has returned or does not respond to standard treatment. It may help shrink tumors or control the disease, and it also aims to find safe dosing.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have confirmed high-grade osteosarcoma, and it has either returned or is not responding to standard treatment
- You are between 2 and 25 years old when you sign consent
- Your scans show at least one measurable tumor spot on CT or MRI that can be tracked over time
- You can expect to live at least 3 months, and your heart, liver, kidneys, and blood counts are within required limits
- You have not had certain prior treatments (including sulfatinib before or multiple VEGF/VEGFR targeted therapies)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether the combination of two drugs, apatinib (a targeted therapy) and liposomal irinotecan (a chemotherapy), can help people with osteosarcoma that has not responded to standard treatments or has spread. The goal is to see if the combination can shrink tumors or slow the disease.
This Phase 2 trial studies HS-20093 in adults with osteosarcoma or other sarcomas that came back or did not respond to standard treatment. It aims to see how well the drug works and whether it is safe for people whose cancer has progressed.
This early-phase study tests whether adding losartan to sunitinib can help control osteosarcoma that has returned or keeps growing after at least one prior treatment. It may help by targeting the cancer’s growth signals and blood supply, but the goal at this stage is mainly to check safety and find workable dosing.
This Phase 1/2 study tests how safe and how well vactosertib works for adolescents and adults with osteosarcoma that has returned, stopped responding, or is getting worse despite prior treatment. You may be able to join if you meet age, cancer, recovery-from-prior-therapy, and health-test requirements.
This Phase 2 trial studies whether surufatinib combined with chemotherapy given before surgery can shrink osteosarcoma and improve outcomes. It may help by attacking the tumor from more than one angle before the main treatment step.
This trial combines four targeted drugs (gefitinib, trametinib, disulfiram, sunitinib) with standard chemotherapy to treat osteosarcoma that has spread or come back. The goal is to see if this drug mix helps shrink tumors or keep them from growing.
Hear when a new Osteosarcoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.